$3.53
+0.13 (+3.82%)
Open$3.56
Previous Close$3.40
Day High$3.59
Day Low$3.40
52W High$25.40
52W Low$16.55
Volume—
Avg Volume384.5K
Market Cap174.73M
P/E Ratio—
EPS$-1.05
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+445.0% upside
Current
$3.53
$3.53
Target
$19.24
$19.24
$16.83
$19.24 avg
$29.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 27.03M | 27.35M | 20.96M |
| Net Income | 5.71M | 6.20M | 4.50M |
| Profit Margin | 21.1% | 22.7% | 21.5% |
| EBITDA | 9.17M | 9.44M | 6.87M |
| Free Cash Flow | 5.73M | 4.10M | 4.11M |
| Rev Growth | +7.1% | -0.5% | +20.5% |
| Debt/Equity | 1.06 | 0.99 | 1.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |